Prognostic Importance of the Platelet Count 100 Days Post Allogeneic Bone Marrow Transplant

Abstract

In a study conducted between July 2016 and December 2020, 110 patients who received ablative allogeneic BMT and survived for at least 100 days, had their platelet counts evaluated 100 days after transplantation. There were 37 cases of AML, 28 cases of CML, 15 cases of NHL, 16 cases of ALL, 9 cases of MDS, and 3 cases of aplastic anaemia. One person was found to have Hodgkin's disease as well as myelofibrosis, according to the report. Only 35.4 percent of those who received a transplant were suffering from active illness, whereas 64.5 percent were in remission, chronic phase, or had aplastic anaemia (low risk). In all, 79% of all transplants were performed on siblings donors, with the remaining 29% performed on unrelated donors. After they have been treated, patients who survive the treatment are observed for an average of 48 months. It was found that having a higher platelet count at 100 days was associated with a higher chance of survival. Those with platelet counts of 30 x10⁹ had a 4-year survival rate (19 percent), those with platelet counts of 30–50 and >50 had survival rates of 41 percent and those with platelet counts >50 had survival rates of 72 percent respectively. In a multivariate study, it was discovered that a low 100-day platelet count (P <0.001) and a high risk of active disease (P=0.009) were the most significant mortality risk factors after allogeneic BMT. It is possible that a person's entire survival might be predicted by their platelet count 100 days following transplantation, according to the authors of the study.